Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 64

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 8
Chunk 64
---
crease in general and administrative expenses.

For the three months ended December 31, 2024,
payroll and related expenses decreased by $1,298,818. This decrease was primarily attributable to a reduction of $872,763 in separation
expenses related to the Separation Agreement with the former Chief Executive Officer that had been recorded in the December 2023 period,
as well as a decrease of $426,055 due to a reduction in headcount. Of the $872,763 of separation expenses related to the departure of
the former Chief Executive Officer, $393,139 related to the acceleration of vesting of stock options.

Professional fees decreased by $290,709, primarily
due to a reduction of $181,380 in legal fees which includes $148,696 decrease resulting from the transition to a new legal firm and $44,000
decrease related to fees incurred for the stock split with no comparable expense in the current period. Additionally, there was a decrease
of $176,434 in scientific and operational consulting fees largely attributable to completed projects. These decreases were partially offset
by a $64,487 increase in investor relations and accounting fees, an $11,101 increase in legal fees related to patent matters, as well
as a $2,618 increase in website services.

The $162,814 decrease in general and administrative
expenses for the quarter was primarily driven by a $253,297 reduction in supplies, largely related to the raw materials and components
used in the manufacturing of the Hemopurifier, with no comparable purchases during the current period. Additionally, there was a $63,686
decrease in insurance expenses associated with a reduced headcount and a $22,708 reduction in various other operating expenses. These
reductions were partially offset by a $176,877 increase in expenses related to our ongoing oncology clinical trials in Australia and India.

 22 

Net Loss

As a result of the changes in expenses noted above,
our comprehensive loss decreased to $1,767,840 in the three months ended December 31, 2024 from $3,458,170 in the three months ended December
31, 2023.

Basic and diluted loss attributable to common
stockholders was ($0.13) for the three months ended December 31, 2024, compared to ($1.37) for the three-month period ended December 31,
2023.

NINE MONTHS ENDED DECEMBER 31, 2024 COMP